BioPorto Logo

BioPorto

An in vitro diagnostics company specializing in biomarkers for early kidney injury detection.

BIOPOR | CO

Overview

Corporate Details

ISIN(s):
DK0011048619
LEI:
5299004SWFL5JAN4W830
Country:
Denmark
Address:
Tuborg Havnevej 15, st., 2900 Hellerup

Description

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-24 10:37 Danish 34.3 KB
2025-11-24 10:37 English 32.7 KB
2025-11-24 10:37 Danish 566.4 KB
2025-11-24 10:37 English 527.4 KB
2025-11-24 10:09 English 7.4 KB
2025-11-24 10:09 Danish 520.8 KB
2025-11-24 10:09 Danish 7.4 KB
2025-11-24 10:09 English 500.5 KB
2025-11-13 19:50 English 12.3 KB
2025-11-13 19:50 Danish 545.9 KB
2025-11-13 19:50 English 511.2 KB
2025-11-13 19:50 Danish 12.2 KB
2025-11-04 22:10 Danish 225.4 KB
2025-11-04 22:10 English 238.1 KB
2025-11-04 22:10 English 18.9 KB

Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioPorto

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioPorto via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.